Treprostinil

Status
Phase 3
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Inhaled Drug
Funder Type
Industry

Drug Details

Inhaled treprostinil is an inhaled medication approved for the treatment of pulmonary arterial hypertension in World Health Organization (WHO) Group 1 patients. Inhaled treprostinil is a synthetic analogue of prostacyclin, a naturally occurring substance in the body, which has effects on dilating blood vessels. Inhaled treprostinil was approved for PAH by the United States Food and Drug Administration (FDA) in 2009 and for PH-ILD in 2021. 

Study Purpose

Study RIN-PF-301 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period.

Find a Clinical Trial 

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >